Elvina Almuradova: DisACcontinuing anti-HER2 treatment in super responders could be considered

Elvina Almuradova, Medical Oncologist Ambassador at European School of Oncology, shared on X:

“Discontinuing anti-HER2 treatment in super responders could be considered, but trial results will be necessary to confirm this approach; meanwhile, hormone receptor status appears to be a major factor for disease progression.”

Source: Elvina Almuradova/X